Study Completed

Hemophilia A

Bayer Identifier:

14344

ClinicalTrials.gov Identifier:

NCT00932555

EudraCT Number:

Not Available

EU CT Number:

Not Available

EffeKt Taiwan- Efficacy and Safety of long-term treatment with KOGENATE® FS in Taiwan

Trial purpose

The aim of this international prospective post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGENATE Bayer/FS in treatment of patients with haemophilia A under daily-life treatment conditions.

Key Participants Requirements

Sex

Male

Age

0 - N/A

Inclusion Criteria
- Patients with diagnosis of hemophilia A, independent of age, treated with KOGENATE FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE FS. For pretreated patients with more than 100 exposure days an inhibitor assessment within three months prior to enrollment should be available; for pretreated patients with less than 100 exposure days an inhibitor assessment at baseline should be available.
Exclusion Criteria

Trial summary

Enrollment Goal

Trial Dates

April 2009 - December 2011

Phase

N/A

Could I Receive a placebo

Products

Kogenate FS (Recombinant Factor VIII, BAY14-2222)

Accepts Healthy Volunteer

Where to participate

Status	Institution	Location
Completed		Many Locations, Taiwan

Primary Outcome

Efficacy and Safety of Kogenate FS
Time Frame:
After 12 months and after 24 months
Safety Issue:
Yes

Trial design

EffeKt Taiwan- Efficacy and Safety of long-term treatment with KOGENATE® FS in Taiwan

Trial Type

Observational

Intervention Type

Biological/Vaccine

Trial Purpose

N/A

Allocation

N/A

Blinding

N/A

Assignment

N/A

Trial Arms

N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to marketed products.